BROMFENAC SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bromfenac Sodium, and what generic alternatives are available?
Bromfenac Sodium is a drug marketed by Alembic, Amring Pharms, Apotex, Chartwell Rx, Coastal Pharms, Eugia Pharma, Gland Pharma Ltd, Lupin Ltd, Rising, and Sentiss. and is included in thirteen NDAs.
The generic ingredient in BROMFENAC SODIUM is bromfenac sodium. Ten suppliers are listed for this compound. Additional details are available on the bromfenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bromfenac Sodium
A generic version of BROMFENAC SODIUM was approved as bromfenac sodium by SENTISS on January 22nd, 2014.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BROMFENAC SODIUM?
- What are the global sales for BROMFENAC SODIUM?
- What is Average Wholesale Price for BROMFENAC SODIUM?
Summary for BROMFENAC SODIUM
![BROMFENAC SODIUM drug patent expirations Drug patent expirations by year for BROMFENAC SODIUM](/p/graph/s/t/BROMFENAC_SODIUM-patent-expirations.png)
![Drug Prices for BROMFENAC SODIUM](/p/graph/drug-price/BROMFENAC+SODIUM.png)
Recent Clinical Trials for BROMFENAC SODIUM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Seoul National University Hospital | Phase 2 |
Ministry of Health, China | N/A |
Sun Yat-sen University | N/A |
Pharmacology for BROMFENAC SODIUM
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for BROMFENAC SODIUM
Paragraph IV (Patent) Challenges for BROMFENAC SODIUM
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
BROMSITE | Ophthalmic Solution | bromfenac sodium | 0.075% | 206911 | 1 | 2017-10-25 |
PROLENSA | Ophthalmic Solution | bromfenac sodium | 0.07% | 203168 | 1 | 2013-07-26 |
US Patents and Regulatory Information for BROMFENAC SODIUM
BROMFENAC SODIUM is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting BROMFENAC SODIUM
PATENT CHALLENGE
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alembic | BROMFENAC SODIUM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 210560-001 | Jun 21, 2019 | AT2 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Eugia Pharma | BROMFENAC SODIUM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 204813-001 | Mar 18, 2022 | AT2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Apotex | BROMFENAC SODIUM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 202620-001 | Jun 23, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |